share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K：重大事件
美股sec公告 ·  03/19 16:10
Moomoo AI 已提取核心信息
Novo Integrated Sciences, Inc. reported on March 19, 2024, that it had entered into a series of agreements and waivers related to a previously issued $70 million unsecured promissory note. The note, with a 15-year term and a maturity date of April 26, 2038, was part of a securities purchase agreement with RC Consulting Group LLC, favoring SCP Tourbillion Monaco. The company faced an Event of Default under the agreement due to non-compliance with Nasdaq's minimum bid price requirements. However, an initial waiver was granted, exempting the company from non-compliance related to the minimum bid price requirement. Subsequently, RC Consulting Group LLC assigned its rights and interest in the agreement and note to RC Consulting Consortium Group LLC. On March 19, 2024, a further...Show More
Novo Integrated Sciences, Inc. reported on March 19, 2024, that it had entered into a series of agreements and waivers related to a previously issued $70 million unsecured promissory note. The note, with a 15-year term and a maturity date of April 26, 2038, was part of a securities purchase agreement with RC Consulting Group LLC, favoring SCP Tourbillion Monaco. The company faced an Event of Default under the agreement due to non-compliance with Nasdaq's minimum bid price requirements. However, an initial waiver was granted, exempting the company from non-compliance related to the minimum bid price requirement. Subsequently, RC Consulting Group LLC assigned its rights and interest in the agreement and note to RC Consulting Consortium Group LLC. On March 19, 2024, a further waiver was agreed upon, allowing the company to use the proceeds of the note for purposes other than those originally restricted, such as repaying debts to officers or investing in other entities. This waiver, known as the March 2024 Waiver, did not affect other terms of the original agreement, which remains in full force.
Novo Integrated Sciences, Inc.于2024年3月19日报告称，它已就先前发行的7000万美元无抵押本票签订了一系列协议和豁免。该票据的期限为15年，到期日为2038年4月26日，是与RC Consulting Group LLC签订的证券购买协议的一部分，该协议有利于摩纳哥SCP Tourbillion LLC。由于不遵守纳斯达克的最低出价要求，该公司根据协议面临违约事件。但是，最初批准了豁免，使该公司免于违反最低出价要求的行为。随后，RC咨询集团有限责任公司将其在协议和附注中的权利和利益转让给了RC咨询联盟集团有限责任公司。2024年3月19日，商定了进一步的豁免，允许公司将票据的收益用于最初限制以外的目的，例如向高管偿还债务或投资其他实体。该豁免被称为2024年3月豁免，并未影响原始协议的其他条款，该协议仍然完全有效。
Novo Integrated Sciences, Inc.于2024年3月19日报告称，它已就先前发行的7000万美元无抵押本票签订了一系列协议和豁免。该票据的期限为15年，到期日为2038年4月26日，是与RC Consulting Group LLC签订的证券购买协议的一部分，该协议有利于摩纳哥SCP Tourbillion LLC。由于不遵守纳斯达克的最低出价要求，该公司根据协议面临违约事件。但是，最初批准了豁免，使该公司免于违反最低出价要求的行为。随后，RC咨询集团有限责任公司将其在协议和附注中的权利和利益转让给了RC咨询联盟集团有限责任公司。2024年3月19日，商定了进一步的豁免，允许公司将票据的收益用于最初限制以外的目的，例如向高管偿还债务或投资其他实体。该豁免被称为2024年3月豁免，并未影响原始协议的其他条款，该协议仍然完全有效。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息